Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Kuoppamäki M[au]:

Search results

Items: 1 to 50 of 52

1.

Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial.

Al-Chalabi A, Shaw P, Leigh PN, van den Berg L, Hardiman O, Ludolph A, Aho VV, Sarapohja T, Kuoppamäki M.

J Neurol Neurosurg Psychiatry. 2019 Oct;90(10):1165-1170. doi: 10.1136/jnnp-2018-320288. Epub 2019 Jul 17.

2.

Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.

Trenkwalder C, Kuoppamäki M, Vahteristo M, Müller T, Ellmén J.

Neurology. 2019 Mar 26;92(13):e1487-e1496. doi: 10.1212/WNL.0000000000007173. Epub 2019 Mar 1.

3.

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.

Kuoppamäki M, Leinonen M, Poewe W.

J Neural Transm (Vienna). 2015 Dec;122(12):1709-14. doi: 10.1007/s00702-015-1449-6. Epub 2015 Sep 7.

4.

[Parkinson's disease associated with a mutation in the PARK2 gene].

Kaasinen V, Hietala M, Kuoppamäki M.

Duodecim. 2015;131(12):1187-90. Finnish.

PMID:
26245049
5.

Oral Levosimendan Increases Cerebral Blood Flow Velocities in Patients with a History of Stroke or Transient Ischemic Attack: A Pilot Safety Study.

Kivikko M, Kuoppamäki M, Soinne L, Sundberg S, Pohjanjousi P, Ellmen J, Roine RO.

Curr Ther Res Clin Exp. 2015 Jan 29;77:46-51. doi: 10.1016/j.curtheres.2015.01.001. eCollection 2015 Dec.

6.

Levosimendan alone and in combination with valsartan prevents stroke in Dahl salt-sensitive rats.

Levijoki J, Kivikko M, Pollesello P, Sallinen J, Hyttilä-Hopponen M, Kuoppamäki M, Haasio K, Gröhn O, Miettinen R, Puoliväli J, Tähtivaara L, Yrjänheikki J, Haapalinna A.

Eur J Pharmacol. 2015 Mar 5;750:132-40. doi: 10.1016/j.ejphar.2015.01.037. Epub 2015 Jan 29.

7.

Entacapone and prostate cancer risk in patients with Parkinson's disease.

Korhonen P, Kuoppamäki M, Prami T, Hoti F, Christopher S, Ellmén J, Aho V, Vahteristo M, Pukkala E, Haukka J.

Mov Disord. 2015 Apr 15;30(5):724-8. doi: 10.1002/mds.26140. Epub 2015 Jan 16.

PMID:
25639262
8.

High sensitive C-reactive protein (hsCRP), cardiovascular events and mortality in the aged: a prospective 9-year follow-up study.

Kuoppamäki M, Salminen M, Vahlberg T, Irjala K, Kivelä SL, Räihä I.

Arch Gerontol Geriatr. 2015 Jan-Feb;60(1):112-7. doi: 10.1016/j.archger.2014.10.002. Epub 2014 Oct 13.

PMID:
25456891
9.

Entacapone did not Increase Prostate Cancer Risk or Mortality in Patients with Parkinson's Disease.

Korhonen P, Kuoppamäki M, Prami T, Hoti F, Christopher S, Ellmén J, Aho V, Vahteristo M, Pukkala E, Haukka J.

Value Health. 2014 Nov;17(7):A393. doi: 10.1016/j.jval.2014.08.870. Epub 2014 Oct 26. No abstract available.

10.

Pooled analysis of phase III with entacapone in Parkinson's disease.

Kuoppamäki M, Vahteristo M, Ellmén J, Kieburtz K.

Acta Neurol Scand. 2014 Oct;130(4):239-47. doi: 10.1111/ane.12278. Epub 2014 Sep 3.

PMID:
25186800
11.

Does high sensitive CRP improve cardiovascular risk prediction in metabolic syndrome among the aged?

Salminen M, Kuoppamäki M, Vahlberg T, Räihä I, Irjala K, Kivelä SL.

Scand Cardiovasc J. 2013 Aug;47(4):210-6. doi: 10.3109/14017431.2013.798427. Epub 2013 May 31.

PMID:
23724977
12.

Metabolic syndrome defined by modified International Diabetes Federation criteria and type 2 diabetes mellitus risk: a 9-year follow-up among the aged in Finland.

Salminen M, Kuoppamäki M, Vahlberg T, Räihä I, Irjala K, Kivelä SL.

Diab Vasc Dis Res. 2013 Jan;10(1):11-6. doi: 10.1177/1479164112442077. Epub 2012 Mar 29.

PMID:
22461662
13.

The effect of different dosing regimens of levodopa/carbidopa/entacapone on plasma levodopa concentrations.

Ingman K, Naukkarinen T, Vahteristo M, Korpela I, Kuoppamäki M, Ellmén J.

Eur J Clin Pharmacol. 2012 Mar;68(3):281-9. doi: 10.1007/s00228-011-1121-5. Epub 2011 Sep 17.

PMID:
21927836
14.

Does levodopa accelerate the pathologic process in Parkinson disease brain?

Parkkinen L, O'Sullivan SS, Kuoppamäki M, Collins C, Kallis C, Holton JL, Williams DR, Revesz T, Lees AJ.

Neurology. 2011 Oct 11;77(15):1420-6. doi: 10.1212/WNL.0b013e318232ab4c. Epub 2011 Sep 14.

PMID:
21917769
15.

Metabolic syndrome and vascular risk: a 9-year follow-up among the aged in Finland.

Salminen M, Kuoppamäki M, Vahlberg T, Räihä I, Irjala K, Kivelä SL.

Acta Diabetol. 2011 Jun;48(2):157-65. doi: 10.1007/s00592-010-0251-z. Epub 2011 Jan 15.

PMID:
21234614
16.

Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa.

Kuoppamäki M, Sauramo A, Korpela K, Vahteristo M, Kailajärvi M, Lehtinen T, Ellmén J.

Int J Clin Pharmacol Ther. 2010 Nov;48(11):756-60.

PMID:
20979935
17.

"Progressive delayed-onset postanoxic dystonia" diagnosed with PANK2 mutations 26 years after onset-an update.

Kojovic M, Kuoppamäki M, Quinn N, Bhatia KP.

Mov Disord. 2010 Dec 15;25(16):2889-91. doi: 10.1002/mds.23153. No abstract available.

PMID:
20925075
18.

The metabolic syndrome defined by modified International Diabetes Federation criteria and mortality: a 9-year follow-up of the aged in Finland.

Salminen M, Kuoppamäki M, Vahlberg T, Räihä I, Irjala K, Kivelä SL.

Diabetes Metab. 2010 Dec;36(6 Pt 1):437-42. doi: 10.1016/j.diabet.2010.05.002. Epub 2010 Aug 12.

PMID:
20708423
19.

Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.

Eggert K, Skogar O, Amar K, Luotonen L, Kuoppamäki M, Leinonen M, Nissinen H, Oertel W.

J Neural Transm (Vienna). 2010 Mar;117(3):333-42. doi: 10.1007/s00702-009-0344-4. Epub 2009 Dec 15.

PMID:
20013007
20.

Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis.

Nissinen H, Kuoppamäki M, Leinonen M, Schapira AH.

Eur J Neurol. 2009 Dec;16(12):1305-11. doi: 10.1111/j.1468-1331.2009.02726.x. Epub 2009 Jun 30.

PMID:
19570145
21.

Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily.

Kuoppamäki M, Korpela K, Marttila R, Kaasinen V, Hartikainen P, Lyytinen J, Kaakkola S, Hänninen J, Löyttyniemi E, Kailajärvi M, Ruokoniemi P, Ellmén J.

Eur J Clin Pharmacol. 2009 May;65(5):443-55. doi: 10.1007/s00228-009-0622-y. Epub 2009 Feb 20.

PMID:
19229530
22.

Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.

Brooks DJ, Leinonen M, Kuoppamäki M, Nissinen H.

J Neural Transm (Vienna). 2008 Jun;115(6):843-9. doi: 10.1007/s00702-008-0025-8. Epub 2008 Feb 8.

PMID:
18259682
23.

L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates.

Kuoppamäki M, Al-Barghouthy G, Jackson MJ, Smith LA, Quinn N, Jenner P.

J Neural Transm (Vienna). 2007 Sep;114(9):1147-53. Epub 2007 Apr 20.

PMID:
17446998
24.

Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.

Smith LA, Jackson MJ, Johnston L, Kuoppamaki M, Rose S, Al-Barghouthy G, Del Signore S, Jenner P.

Clin Neuropharmacol. 2006 May-Jun;29(3):112-25.

PMID:
16772809
25.

MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome.

Zeng BY, Iravani MM, Lin ST, Irifune M, Kuoppamäki M, Al-Barghouthy G, Smith L, Jackson MJ, Rose S, Medhurst AD, Jenner P.

Eur J Neurosci. 2006 Apr;23(7):1766-74.

PMID:
16623833
26.

Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia.

Iravani MM, Costa S, Al-Bargouthy G, Jackson MJ, Zeng BY, Kuoppamäki M, Obeso JA, Jenner P.

Eur J Neurosci. 2005 Sep;22(6):1305-18.

PMID:
16190886
27.

[Paroxysmal kinesigenic dyskinesia (PKD) a rare motion disorder].

Kuoppamäki M, Keränen T.

Duodecim. 2005;121(7):769-71. Finnish. No abstract available.

PMID:
15909964
28.

Parkinsonism following bilateral lesions of the globus pallidus: performance on a variety of motor tasks shows similarities with Parkinson's disease.

Kuoppamäki M, Rothwell JC, Brown RG, Quinn N, Bhatia KP, Jahanshahi M.

J Neurol Neurosurg Psychiatry. 2005 Apr;76(4):482-90.

29.

Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates.

Smith LA, Jackson MJ, Al-Barghouthy G, Rose S, Kuoppamaki M, Olanow W, Jenner P.

Mov Disord. 2005 Mar;20(3):306-14.

PMID:
15490461
30.
31.

Slowly progressive cerebellar ataxia and cervical dystonia: clinical presentation of a new form of spinocerebellar ataxia?

Kuoppamäki M, Giunti P, Quinn N, Wood NW, Bhatia KP.

Mov Disord. 2003 Feb;18(2):200-6. Review.

PMID:
12539216
32.

Progressive delayed-onset dystonia after cerebral anoxic insult in adults.

Kuoppamäki M, Bhatia KP, Quinn N.

Mov Disord. 2002 Nov;17(6):1345-9.

PMID:
12465080
33.

Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.

Kuoppamäki M, Al-Barghouthy G, Jackson M, Smith L, Zeng BY, Quinn N, Jenner P.

Mov Disord. 2002 Nov;17(6):1312-7.

PMID:
12465074
34.

Differential effects of fluoxetine and citalopram treatments on serotonin 5-HT(2C) receptor occupancy in rat brain.

Pälvimäki EP, Kuoppamäki M, Syvälahti E, Hietala J.

Int J Neuropsychopharmacol. 1999 Jun;2(2):95-99.

PMID:
11281975
35.

Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study.

Kanerva H, Vilkman H, Någren K, Kilkku O, Kuoppamäki M, Syvälahti E, Hietala J.

Psychopharmacology (Berl). 1999 Jul;145(1):76-81.

PMID:
10445375
36.

Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia.

Hietala J, Syvälahti E, Vilkman H, Vuorio K, Räkköläinen V, Bergman J, Haaparanta M, Solin O, Kuoppamäki M, Eronen E, Ruotsalainen U, Salokangas RK.

Schizophr Res. 1999 Jan 4;35(1):41-50.

PMID:
9988840
37.

Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography.

Tiihonen J, Vilkman H, Räsänen P, Ryynänen OP, Hakko H, Bergman J, Hämäläinen T, Laakso A, Haaparanta-Solin M, Solin O, Kuoppamäki M, Syvälahti E, Hietala J.

Mol Psychiatry. 1998 Mar;3(2):156-61.

PMID:
9577840
38.

Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation.

Pälvimäki EP, Majasuo H, Kuoppamäki M, Männistö PT, Syvälahti E, Hietala J.

Psychopharmacology (Berl). 1998 Mar;136(2):99-104.

PMID:
9551765
39.

Effects of lorazepam administration on striatal dopamine D2 receptor binding characteristics in man--a positron emission tomography study.

Hietala J, Kuoppamäki M, Någren K, Lehikoinen P, Syvälahti E.

Psychopharmacology (Berl). 1997 Aug;132(4):361-5.

PMID:
9298513
40.

Effects of clozapine metabolites and chronic clozapine treatment on rat brain GABAA receptors.

Wong G, Kuoppamäki M, Hietala J, Lüddens H, Syvälahti E, Korpi ER.

Eur J Pharmacol. 1996 Oct 31;314(3):319-23.

PMID:
8957253
41.

Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography.

Tiihonen J, Kuoppamäki M, Någren K, Bergman J, Eronen E, Syvälahti E, Hietala J.

Psychopharmacology (Berl). 1996 Aug;126(4):277-80.

PMID:
8878342
42.

Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor.

Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J.

Psychopharmacology (Berl). 1996 Aug;126(3):234-40.

PMID:
8876023
43.

Chronic citalopram and fluoxetine treatments upregulate 5-HT2c receptors in the rat choroid plexus.

Laakso A, Pälvimäki EP, Kuoppamäki M, Syvälahti E, Hietala J.

Neuropsychopharmacology. 1996 Aug;15(2):143-51.

44.

Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients.

Hietala J, Syvälahti E, Vuorio K, Räkköläinen V, Bergman J, Haaparanta M, Solin O, Kuoppamäki M, Kirvelä O, Ruotsalainen U, et al.

Lancet. 1995 Oct 28;346(8983):1130-1.

PMID:
7475604
45.
46.

Regulation of serotonin 5-HT2C receptors in the rat choroid plexus after acute clozapine treatment.

Kuoppamäki M, Seppälä T, Syvälahti E, Hietala J.

Eur J Pharmacol. 1994 Oct 14;269(2):201-8.

PMID:
7851496
47.

Dopamine D2 receptor gene expression in rat lines selected for differences in voluntary alcohol consumption.

Syvälahti EK, Pohjalainen T, Korpi ER, Pälvimäki EP, Ovaska T, Kuoppamäki M, Hietala J.

Alcohol Clin Exp Res. 1994 Aug;18(4):1029-31.

PMID:
7978083
48.

Up-regulation of beta 1-adrenergic receptors in rat brain after chronic citalopram and fluoxetine treatments.

Pälvimäki EP, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J.

Psychopharmacology (Berl). 1994 Aug;115(4):543-6.

PMID:
7871100
49.

5-HT1C receptor-mediated phosphoinositide hydrolysis in the rat choroid plexus after chronic treatment with clozapine.

Kuoppamäki M, Pälvimäki EP, Syvälahti E, Hietala J.

Eur J Pharmacol. 1994 Apr 1;255(1-3):91-7.

PMID:
8026557
50.

Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists.

Kuoppamäki M, Syvälahti E, Hietala J.

Eur J Pharmacol. 1993 Apr 15;245(2):179-82.

PMID:
8387927

Supplemental Content

Loading ...
Support Center